Viridian Therapeutic (VRDN) PT Raised to $43 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
Go back to Viridian Therapeutic (VRDN) PT Raised to $43 at Wedbush
June 29, 2026 9:51 AM EDT
DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization.
... More
June 26, 2026 6:00 PM EDT
- First approved treatment for thyroid eye disease (TED) with labeling that includes data for both active and chronic TED -
- In two pivotal phase 3 clinical trials, Lumvoa treatment showed rapid, consistent, and durable reductions of the key signs and symptoms of both active and chronic TED -
- Lumvoa is the first approved product for TED to show a statistically significant effect in both diplopia response and complete resolution of diplopia in active and chronic disease -
- Viridian plans to... More
